Progressive multifocal leukoencephalopathy in patients with immunovirological control and at least 6 months of combination antiretroviral therapy.
Dalla-Pozza P, Hentzien M, Allavena C, Doe de Maindreville A, Bouiller K, Valantin MA, Lafont E, Zaegel-Faucher O, Cheret A, Martin-Blondel G, Cotte L, Bani-Sadr F; and the Dat’AIDS study group.
AIDS. 2022 Mar 15;36(4):539-549. doi: 10.1097/QAD.0000000000003145.
PMID:34873087
Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review.
Sharma K, Tolaymat S, Yu H, Elkhooly M, Jaiswal S, Jena A, Kakara M, Sriwastava S.
J Neurol Sci. 2022 Dec 15;443:120459. doi: 10.1016/j.jns.2022.120459. Epub 2022 Oct 14.
PMID:36283150
Survival and prognostic factors of progressive multifocal leukoencephalopathy in people living with HIV in modern ART era.
Jiang R, Song Z, Liu L, Mei X, Sun J, Qi T, Wang Z, Song W, Tang Y, Yang J, Xu S, Zhao B, Shen Y, Zhang R, Chen J.
Front Cell Infect Microbiol. 2023 Nov 8;13:1208155. doi: 10.3389/fcimb.2023.1208155. eCollection 2023.
PMID:38029233
Extensive progressive multifocal leukoencephalopathy as the first manifestation of AIDS.
Couto LPD, Barcelos V, Goulart A.
Rev Soc Bras Med Trop. 2021 Apr 12;54:e0073. doi: 10.1590/0037-8682-0073-2021. eCollection 2021.
PMID:33886815
Progressive multifocal leukoencephalopathy in AIDS: a clinicopathologic study and review of the literature.
von Einsiedel RW, Fife TD, Aksamit AJ, Cornford ME, Secor DL, Tomiyasu U, Itabashi HH, Vinters HV.